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Martin Bialer,6 Fan Xia,7 Parisa Hemati,1 James Riviello,1 Michele Mehaffey,4 Thomas Besnard,3
Emily Becraft,8 Alexandrea Wadley,9 Anya Revah Politi,1 Sophie Colombo,1 Xiaolin Zhu,1 Zhong Ren,1
Ian Andrews,10 Tracy Dudding-Byth,11,12 Amy L. Schneider,13 Geoffrey Wallace,14 University of
Washington Center for Mendelian Genomics, Aaron B.I. Rosen,4 Susan Schelley,8 Gregory M. Enns,8
Pierre Corre,15 Joline Dalton,16 Sandra Mercier,3 Xe´nia Latypova,3 Se´bastien Schmitt,3 Edwin Guzman,1
Christine Moore,6 Louise Bier,1 Erin L. Heinzen,1 Peter Karachunski,16 Natasha Shur,17 Theresa Grebe,18
Alice Basinger,19 Joanne M. Nguyen,20 Ste´phane Be´zieau,3 Klaas Wierenga,9 Jonathan A. Bernstein,8
Ingrid E. Scheffer,13,21,22 Jill A. Rosenfeld,7 Heather C. Mefford,4 Bertrand Isidor,3
and David B. Goldstein1,*
Whole-exome sequencing of 13 individuals with developmental delay commonly accompanied by abnormal muscle tone and seizures
identified de novo missense mutations enriched within a sub-region of GNB1, a gene encoding the guanine nucleotide-binding
protein subunit beta-1, Gb. These 13 individuals were identified among a base of 5,855 individuals recruited for various undiagnosed
genetic disorders. The probability of observing 13 or more de novo mutations by chance among 5,855 individuals is very low
(p ¼ 7.1 3 1021), implicating GNB1 as a genome-wide-significant disease-associated gene. The majority of these 13 mutations affect
known Gb binding sites, which suggests that a likely disease mechanism is through the disruption of the protein interface required
for Ga-Gbg interaction (resulting in a constitutively active Gbg) or through the disruption of residues relevant for interaction between
Gbg and certain downstream effectors (resulting in reduced interaction with the effectors). Strikingly, 8 of the 13 individuals recruited
here for a neurodevelopmental disorder have a germline de novo GNB1 mutation that overlaps a set of five recurrent somatic tumor
mutations for which recent functional studies demonstrated a gain-of-function effect due to constitutive activation of G protein down-
stream signaling cascades for some of the affected residues.Neurodevelopmental disability represents a collection of
clinically and biologically heterogeneous disorders. How-
ever, when a genetic disorder lacks distinguishing clinical
features, it has proven challenging to stratify populations
of affected individuals for phenotypically driven gene dis-
covery. A recent strategy that has proven powerful for
discovering disease-associated genes among more clini-
cally heterogeneous populations has been large whole-
exome sequencing studies on individuals presenting with
relatively non-specific clinical features and identifying
genes with excess de novo mutations in the affected popu-
lation.1–3 Clinical sequencing labs are finding that a third
of individuals recruited for undiagnosed genetic disorders
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plained by pathogenic de novo mutations.3–6
Here, we describe 13 individuals (Table 1) with a previ-
ously unrecognized genetic condition characterized by
global developmental delay (13/13), hypotonia (11/13), sei-
zures (10/13), ophthalmologicalmanifestations (8/13), and
growth delay (6/13) accompanied by additional variable
symptoms (Table 2). Clinical summaries for all 13 affected
individuals are available in the Supplemental Note. These
13 individuals were found to have a de novo missense mu-
tation inGNB1 (MIM: 139380), the gene encoding guanine
nucleotide-bindingprotein (Gprotein) subunit beta-1 (Gb).
GNB1 encodes a ubiquitously7 present b subunit of
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Table 1. Comparison of Symptoms among 13 Individuals
Symptoms Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6
Mutation
(GRCh37;
GenBank:
NM_002074.4)
chr1: g.1737954T>C chr1: g.1737948T>C chr1: g.1737942A>T chr1: g.1737942A>G chr1: g.1735987T>C chr1: g.1718817C>T
c.227A>G c.233A>G c.239T>A c.239T>C c.301A>G c.976G>A
p.Asp76Gly p.Lys78Arg p.Ile80Asn p.Ile80Thr p.Met101Val p.Ala326Thr
Ethnicity Ashkenazi mixed Ashkenazi
and Sephardic Jewish
mixed Ashkenazi
and Sephardic Jewish
North African European European
Gender, Age M, 8.5 years M, 13 months M, 5 years F, 4 years M, 19 years F, 17 years
Developmental
delay
yes yes yes yes yes yes
Abnormal muscle
tone
yes (persistent
hypotonia)
yes (initially
presented with
hypotonia, followed
by improved tone in
extremities)
yes (profound
hypotonic
quadriparesis, central
hypotonia)
severe hypotonia of
axis and lower limbs,
dystonic hypertonia
of upper limbs
no mild hyper-reflexia,
mild hypotonia
Epilepsy no infantile spasms 9 months: generalized
epilepsy onset
no infantile spasms,
absence seizures,
nonconvulsive
status epilepticus,
focal seizures
1 year: febrile status
epilepticus followed
by afebrile focal
convulsive seizures
and absence and
atonic seizures;
14 years: focal
hyperkinetic
sleep-related seizures
EEG 8 years: normal 6 months:
hypsarrhythmia,
VEEG captured
infantile spasms
15 months: generalized
subcortical alterations;
3 years: generalized
epileptiform process
unknown 7, 10, and 11 months:
modified
hypsarrhythmia;
2 years: normal;
3 years: multifocal and
2 Hz GSW
14 months: normal;
5 years: L and
R posterior temporal
epileptiform activity
MRI 3 years: normal 6 months: normal 14 months: bilateral
polymicrogyria,
delayed myelination
11 months: normal scattered, non-specific
T2 white-matter
abnormalities
11 months: normal
Ophthalmological
Disorder
no strabismus cortical vision
impairment
slow ocular pursuit
response
no no
Growth delays:
height and weight
height at 10th–25th
percentile, weight
at 10th percentile
height < 3rd
percentile, weight
at 12th percentile
failure to thrive:
weight and height
below 5th percentile
height at 2nd
percentile, weight
at 1st percentile
height just above
75th percentile,
weight just below
50th percentile
height at 10th–25th
percentile, weight
just above
3rd percentile
Microcephaly no no no no no no
Macrocephaly OFC at 75th–90th
percentile
no no no no no
Dysmorphic
features
no no mild hypotonic face,
outward flexed and
deviated great toes
cleft palate no prominent central
incisors, short
philtrum, long
tapering fingers,
narrow hands,
joint hypermobility
Additional
features
vocal tics and
ADHD, paternally
inherited 259 kb
interstitial deletion
at 22q11.1
no delayed hearing
potentials
peripheral
hypothyroidism,
asthma, adducted
thumbs
autism spectrum
disorder, behavioral
problems
maternally inherited
7q11.21 0.3 Mb
duplication,
aggressive behavior,
drooling
Abbreviations are as follows: M, male; F, female; VEEG, video electroencephalogram; GSW, generalized spike-and-wave; L, left; R, right; OFC, occipitofrontal circumference;
and ADHD, Attention-deficit hyperactivity disorder.subunits Ga and Gg, which are essential to the signaling
function of G-protein-coupled receptors (GPCRs). The as-
sociation between Ga and Gbg covers the interaction sites
on both the a subunit and the Gbg dimer, thus preventing
effector interactions and rendering the G protein inactive.
A ligand binding to the GPCR promotes activation where
Ga disassociates from the Gbg dimer and the GPCR. The
disassociation makes Gbg free to regulate various effector1002 The American Journal of Human Genetics 98, 1001–1010, Mayproteins and signaling cascades, including interactions
with a variety of enzymes and ion channels. Some effectors
directly regulated by Gbg include activation of adenylyl
cyclase 2, interactions with b-adrenergic receptor kinase 1,
inhibition of calcium channels, activation of potassium
channels, activation of phospholipase C-b2, and activa-
tion of class IB phosphoinositide 3-kinases.8 Yoda and col-
leagues recently used proteomic analysis to show that5, 2016
Individual 7 Individual 8 Individual 9 Individual 10 Individual 11 Individual 12 Individual 13
chr1: g.1737953A>C chr1: g.1735987T>C chr1: g.1737952C>T chr1: g.1737942A>G chr1: g.1737942A>G chr1: g.1737942A>T chr1: g.1736004A>G
c.228T>G c.301A>G c.229G>A c.239T>C c.239T>C c.239T>A c.284T>C
p.Asp76Glu p.Met101Val p.Gly77Ser p.Ile80Thr p.Ile80Thr p.Ile80Asn p.Leu95Pro
American (European) mixed European and
fractional Filipino
mixed Mexican,
German, and Spanish
American (European) mixed European American (European) Hispanic
M, 8 years F, 20 years M, 11 years M, 4 years M, 10 years M, 6 years F, 4 years
yes yes yes yes yes yes yes
hypertonia
(hemiplegia)
hypotonia at 2 years,
gross motor
milestone delay in
toddlerhood, mildly
low muscle tone in
childhood
presented with
hypotonia, diagnosed
with hypotonic
cerebral palsy (slowly
improving)
6 months: poor head
control, severe
hypotonia, and
non-ambulatory,
severe oropharyngeal
dysphagia
diffuse severe
hypotonia, remains
non-ambulatory
initially presented
with hypotonia, has
developed hypertonia
in the extremities
hypotonia of axis,
progression to
hypertonia of
extremities
4 years: hemiclonic
seizures followed
by complex partial
status
11 years: onset of
tonic-clonic seizures
no 2 years: onset of head
drops and myoclonic
seizures
9 years: onset of
focal seizures
4 years: onset of
focal seizures
4 months: tonic
posturing of the
arms and occasional
generalized
upper-body
myoclonus
burst suppression 4 years: normal;
11 years: diffuse
slowing and rare
right temporal spikes
mild to moderate
generalized slowing
without focal,
lateralizing, or
epileptiform features
2 years: generalized
paroxysmal epileptiform
activity, myoclonic
seizure with generalized
paroxysmal polyspike
slow-wave activity
9 years: multifocal
spikes and
generalized
background slowing
4 years: high-
amplitude
background with
occipital slowing,
multifocal
epileptiform
discharges
4 months: multifocal
epileptiform
discharges from
both posterior
quadrants, right
temporoparietal
sharp waves
abnormal (see
Supplemental
Note)
3 and 11 years:
normal
questionable cortical
thickening on left
side along sylvian
fissures
7 months: normal;
2.5 years: abnormal
(see Supplemental Note)
normal 1 month: normal 4 months: normal
strabismus, no
fixing or
following
strabismus
(intermittent
left esotropia)
no strabismus (intermittent
left esotropia),
multivectorial
nystagmus (unspecified)
nystagmus cortical vision
impairment
horizontal and
vertical nystagmus,
cortical vision loss
failure to thrive episode of
unexplained
weight loss at
15 years
height at 50th–75th
percentile, weight at
10th–25th percentile
height and weight at
50th percentile at 3 years
height and weight
at 1st percentile
height and
weight < 1st
percentile
height and
weight < 3rd
percentile
no no no no no no <3rd percentile
no birth: OFC at
96th percentile
no 2 years: OFC ¼ 54 cm;
3 years: OFC ¼ 55 cm
no no no
pectus excavatum,
high-arched palate
no no no no ears with overfolded
helices, limited elbow
extension, clenched
hand
cleft palate
hydronephrosis
due to bilateral
ureteropelvic
junction
obstruction
2 years: autism,
developmental
regression of
language; now:
non-verbal with
significant receptive
language
pes planus, attention
deficit hyperactivity
disorder
severe receptive and
expressive language
disorder
2 years: mild
bilateral
hydronephrosis,
regression of
language; now:
non-verbal
bilateral moderate
to severe
sensorineural
hearing loss
maternally inherited
1.5 Mb loss of
4q34–3q35.1mutant GNB1-expressing cells had increased activation of
the AKT, mTOR, and ERK pathways.9
GNB1 has additional literature support for its candidacy
as a gene associated with neurodevelopmental disease. It is
a member of the N-methyl-D-aspartic acid (NMDAR)
synaptic transmission gene set10 and the set of 842 fragile
X mental retardation protein (FMRP) target genes.11 Both
the NMDAR- and FMRP-associated gene sets have beenThe Americrepeatedly implicated in neurodevelopmental and ne-
uropsychiatric disorders, such as epileptic encepha-
lopathies,1,2 autism,12,13 and schizophrenia.14 Moreover,
GNB1 directly interacts with multiple genes encod-
ing disease-associated Ga subunits, including GNAO1
(MIM: 139311; associated with epileptic encephalopathy
[MIM: 615473]), GNAI3 (MIM: 139370; associated with
auriculocondylar syndrome 1 [MIM: 602483]), GNAT2an Journal of Human Genetics 98, 1001–1010, May 5, 2016 1003
Table 2. Clinical Features Shared among Three or More Individuals with a GNB1 Germline De Novo Mutation
Description of HPO Term HPO Term
No. of
Individuals
(of 13)
c.227A>G
(p.Asp76Gly)
c.228T>G
(p.Asp76Glu)
c.229G>A
(p.Gly77Ser)
c.233A>G
(p.Lys78Arg)
c.239T>A
(p.Ile80Asn)
(of two)
c.239T>C
(p.Ile80Thr)
(of three)
c.284T>C
(p.Leu95Pro)
c.301A>G
(p.Met101Val)
(of two)
c.976G>A
(p.Ala326Thr)
Global developmental delay HP:0001263 13 þ þ þ þ þþ þþþ þ þþ þ
Hypotonia HP:0001252 11 þ  þ þ þþ þþþ þ þ þ
Seizures HP:0001250 10  þ  þ þþ þþ þ þþ þ
Growth delay HP:0001510 6    þ þþ þþ þ  
Multifocal epileptiform discharges HP:0010841 5     þ þþ þ þ 
Expressive language delay HP:0002474 4      þþ þ þ 
Failure to thrive HP:0001508 4  þ   þ þ þ  
Feeding difficulties HP:0011968 4    þ þþ  þ  
Intellectual disability HP:0001249 4 þ      þ þ þ
Limb hypertonia HP:0002509 4  þ   þ þ þ  
Strabismus HP:0000486 4  þ  þ  þ þ  
Cortical visual impairment HP:0100704 3     þþ  þ  
Developmental regression HP:0002376 3      þ  þþ 
Early-onset hypotonia HP:0008947 3 þ   þ þ    
EEG with generalized epileptiform
discharges
HP:0011198 3    þ  þ  þ 
Focal seizures with impairment
of awareness
HP:0002384 3  þ   þ   þ 
Generalized tonic-clonic seizures HP:0002069 3        þþ þ
Inability to walk HP:0002540 3      þþ þ  
Nystagmus HP:0000639 3      þþ þ  
Abbreviations are as follows: HPO, Human Phenotype Ontology; and EEG, electroencephalogram.
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(MIM: 139340; associated with achromatopsia 4 [MIM:
613856]), GNAS (MIM: 139320; associated with pseudohy-
poparathyroidism Ia [MIM: 103580), Ib [MIM: 603233],
and Ic [MIM: 612462], pseudopseudohypoparathyroidism
[MIM: 612463], and somatic-mosaic McCune-Albright
syndrome [MIM: 174800]), GNAL (MIM: 139312; associ-
ated with dystonia 25 [MIM: 615073]), GNAQ (MIM:
600998; associated with somatic-mosaic Sturge-Weber
syndrome [MIM: 185300]), and GNA11 (MIM: 139313;
associated with hypocalcemia [MIM: 615361] and type II
hypocalciuric hypercalcemia [MIM: 145981]).
Consistent with an important developmental role, mice
homozygous for a disrupted Gnb1 Gt(prvSStrap)4B8Yiw
(MGI: 4438390) experience partial perinatal lethality and
lethality throughout fetal growth and development.15,16
Moreover, embryos homozygous for mutant Gnb1 show an
excess of neurological phenotypes (including abnormal
brainmorphology, decreased cell proliferation, exencephaly,
decreased brain size, abnormal neural plate morphology,
abnormal embryonic neuroepithelium morphology, ab-
normal neuronal precursor proliferation, abnormal cortical
ventricular zone morphology, and abnormal neuron differ-
entiation), whereas pupswithout neural-tube defects surviv-
ingup topostnatal day2alsodisplay thincerebral cortex and
abnormal suckling behavior.15
GNB1 is found deleted in some individuals with chromo-
some 1p36 deletion syndrome (MIM: 607872), which in-
cludes intellectual disability, developmental delay, seizures
(including infantile spasms), andmuscular hypotonia. Five
individuals with 200–823 kb overlapping 1p36.33 dele-
tions were reported to have classic features of the
1p36.33 syndrome.17 The smallest region of overlap found
across the five individuals was a 174 kb stretch including
GNB1, CALML6, TMEM52, C1ORF222, and KIAA1751.17
The clinical features most commonly shared (by more
than two of the five individuals) included straight eye-
brows (n ¼ 3), a broad nasal root (n ¼ 3), a pointed chin
(n ¼ 3), abnormally low-set ears (n ¼ 4), developmental
delay (n ¼ 5), expressive-language problems (n ¼ 4),
behavioral problems (n ¼ 4), and neonatal hypotonia
(n ¼ 3). Our 13 individuals do not share the dysmorphol-
ogies reported among these individuals with 1p36.33 syn-
drome, but they do share neurodevelopmental and seizure
features. Because the disease-associated gene is not yet
known, this work further suggests that GNB1 is a good
candidate for playing a causal role in 1p36.33 syndrome.
However, unlike the existing mouse knockout models
and the human 1p36.33 deletion syndrome, which repre-
sent possible GNB1 haploinsufficient phenotypes, the ex-
isting functional studies performed by Yoda and colleagues
showed that some of our 13 missense de novo mutations
within the Gbg interaction region act as activating muta-
tions that enhance or continuously activate downstream
signaling pathways.9
Our 13 unrelated individuals with a de novo germline
mutation in GNB1 range from 13 months to 20 years of
age (Table 1 and Supplemental Note). Six of the individualsThe Americhad trio whole-exome sequencing (WES) performed after
written informed consent was obtained through an
institutional-review-board-approved research study at the
Institute for Genomic Medicine at Columbia University
(protocol AAAO8410, individuals 1–3), Centre Hospitalier
Universitaire Nantes (individual 4), the Department of
Pediatrics at the University of Washington (protocol
48919, individual 5), and the University of Melbourne
(H2007/02961, individual 6).
For all six trios, DNA was extracted from maternal,
paternal, and proband samples, exome sequenced on a
HiSeq 2500 with the Kapa Biosystem’s Library Preparation
Kit, and whole-exome captured with Nimblegen SeqCap
EZ v.3.0 (individuals 1–3), SeqCap EZ v.2.0 (individuals
5 and 6), or Agilent SureSelect v.5 (individual 4). Two
paired-end 100 bp reads were used for the exome-capture
sequencing. Raw reads were processed with pipelines based
on the Genome Analysis Toolkit (GATK) best-practices
protocol. For individuals 1–3, trio sequence data were
analyzed with an updated version of our established trio
sequencing framework,4 which identifies ‘‘qualifying’’ ge-
notypes not observed in the parents, 4,326 control individ-
uals from the Institute for Genomic Medicine, or two
external databases of 6,503 and 60,706 control individuals
provided by the National Heart, Lung, and Blood Institute
(NHLBI) Exome Sequencing Project (ESP6500SI [March
2013 release]) and the Exome Aggregation Consortium
(ExAC Browser v.0.3 [January 2015 release]), respectively
(Figure S1A). Individual 4’s genotypes were screened
against ESP6500SI, ExAC Browser v.0.3, the Genome of
the Netherlands (GoNL) database, and the Japanese Hu-
man Genetic Variation Database, and a screening similar
to that in Figure S1A was used. Genotypes of individuals
5 and 6 were screened against ESP6500SI, ExAC Browser
v.0.3, dbSNP, and 1000 Genomes (Figure S1B). For individ-
uals 1–3, qualifying variants were identified on the basis of
four main modes of inheritance: compound heterozygous,
newly homozygous, X-linked hemizygous, and putatively
de novo (Figure S1).4We found that individual 1 had three,
individual 2 had four, and individual 3 had two qualifying
genotypes. Individuals 4 and 5 had two qualifying geno-
types, whereas individual 6 had only the single qualifying
genotype (Table S2).
For individuals 7–13, only the probands were sequenced
with the proband-only exome sequencing approach from
Baylor Miraca Genetics Laboratories (BMGL).5,18 Upon
identification of the GNB1 de novo mutations in individ-
uals 1–6, the probands and parents of trios 7–13 were
Sanger sequenced for the GNB1 missense variants, and
this showed that the variants had arisen de novo in these
seven additional individuals.
All 13 individuals were found to have a Sanger-vali-
dated GNB1 de novo missense mutation (GenBank: NM_
002074.4): c.227A>G (p.Asp76Gly) in individual 1,
c.228T>G (p.Asp76Glu) in individual 7, c. 229G>A
(p. Gly77Ser) in individual 9, c.233A>G (p.Lys78Arg) in in-
dividual 2, c.239T>A (p.Ile80Asn) in individuals 3 andan Journal of Human Genetics 98, 1001–1010, May 5, 2016 1005
12, c.239T>C (p.Ile80Thr) in individuals 4, 10, and 11,
c.284T>C (p.Leu95Pro) in individual 13, c.301A>G
(p.Met101Val) in individuals 5 and 8, and c.976G>A
(p.Ala326Thr) in individual 6. We found that the
Combined Annotation Dependent Depletion (CADD)
score predicted all GNB1 de novo missense mutations
affecting our 13 individuals to be among the 1%
most deleterious substitutions in the human genome
(Table S3).19
A list of Human Phenotype Ontology (HPO)20 terms
were defined for each of the 13 individuals (Table S4). For
three GNB1 residues, we were able to use the HPO terms
to ask whether individuals sharing a GNB1 substitution
also share certain features more often with each other
than with individuals affected at other GNB1 residues.
We found that four of the five individuals with a p.Ile80
substitution reported growth delay (HP: 0001510),
whereas six of the remaining eight individuals did not.
Both dystonia and dysphagia were shared among two of
five individuals with a p.Ile80 substitution but were not re-
ported among the other eight individuals. The two individ-
uals sharing a p.Met101 substitution were both diagnosed
with autism spectrum disorder, which was not assigned
among the remaining 11 individuals. These two individ-
uals with a p.Met101 substitution were phenotyped at
different recruitment sites. A single person (individual 3)
also presented with polymicrogyria, a rare brain malforma-
tion frequently resulting from mutations affecting the
PI3K-AKT-mTOR pathway.21 Although these genotype-
phenotype correlations are suggestive, reliably deter-
mining the phenotypic consequences of the different
mutations will require a larger number of individuals
with GNB1-related neurodevelopmental disease.
The identification of multiple missense de novo mu-
tations in GNB1 is remarkable given that GNB1 is sig-
nificantly depleted of functional variation in the general
population—suggesting that GNB1 might be under strong
purifying selections as a result of critical homeostatic roles.
Using the ExAC reference cohort, we tallied the unique
GNB1 consensus coding sequence (CCDS) protein-coding
variants at 105 and the subset considered non-synony-
mous at 29 (27.6%). Given the sequence context of
GNB1, we expect that 77.6% of all simulated (possible)
GNB1 variants would result in a non-synonymous effect.
Thus, it is clear from the standing variation in the human
population that GNB1 is under strong purifying selection
(p ¼ 2.1 3 1027, two-tailed binomial exact test). Multiple
genic-intolerance metrics consistently support the premise
that GNB1 is intolerant to functional variation.22–24 How-
ever, to formally assess whether we have securely impli-
cated GNB1 as a gene associated with disease, we adopted
the framework established in the large trio sequencing
efforts that have focused on estimating the mutation rate
in genes and then asking whether the observed total
burden of de novo mutations is beyond what could be ex-
plained by chance.1,2,25,26 The total subject base from
which our 13 individuals were identified is 5,855 individ-1006 The American Journal of Human Genetics 98, 1001–1010, Mayuals recruited from multiple sequencing clinics that have
ascertained individuals with a presumed genetic disorder
of unknown cause. Using the underlying mutation rate
of GNB1,27 we calculated the probability of observing 13
or more de novo mutations by chance among 5,855
individuals to be p ¼ 7.1 3 1021, which survives correc-
tion for the 18,669 protein-coding genes routinely tested
in exome sequencing by approximately 15 orders of
magnitude. Importantly, and independently of whether
GNB1 is considered an intolerant gene, this means that
GNB1 is now securely implicated as a genome-wide-signif-
icant disease-associated gene after we account for all
considered individuals; however, the fact that GNB1 is
intolerant makes the mutational excess more remarkable,
as does the clear localization of the mutations that cause
disease.
Nine of the 13GNB1mutations affect a residue coded for
in exon 6 (chr1: g.1737912–1737979; GRCh37). Exon 6
represents only 6.4% of the total GNB1 protein-coding
sequence, and therefore finding 9 of the 13 mutations
in this exon by chance is highly improbable (p ¼
1.0 3 108, two-tailed binomial exact test). The nine de
novo GNB1 (GenBank: NM_002074.4) mutations in exon
6 affect closely spaced residues: p.Asp76Gly, p.Asp76Glu,
p.Gly77Ser, p.Lys78Arg, p.Ile80Asn, and p.Ile80Thr
(Figure 1). The stretch of sequence that overlaps exon 6 is
known to be the sequence relevant for the interaction be-
tween Ga and Gbg in the G protein complex.8
Recently, GNB1 somatic mutations were found to asso-
ciate with hematological transformation and also with
therapeutic resistance to different kinase inhibitors in the
presence of additional driver oncogenic mutations.9 Yoda
and colleagues identified a catalog of 113 somatic muta-
tions from tumor sequencing collections (83 unique vari-
ants), available in Table S1 from Yoda et al.9 In particular,
among their identified catalog of mutations, they identi-
fied five GNB1 and GNB2 (MIM: 139390) loci that they
highlighted as sites of recurrent (more than two) somatic
missense mutations. The five residues affected by somatic
mutations were Lys57 (11 mutations), Lys78 (three muta-
tions), Ile80 (eight mutations), Lys89 (four mutations),
and Met101 (three mutations). All five of these residues
are located along the Gb protein surface that interacts
with Ga subunits and downstream effectors.8 Remarkably,
8 of our 13 individuals have a germline de novo GNB1
missensemutation that overlaps one of these five recurrent
oncogenic amino acid residues (Figure 1).9 Through multi-
ple lines of functional evidence, Yoda and colleagues
showed that these recurrent somatic missense mutations
confer cytokine-independent growth and activate canoni-
cal G protein signaling downstream of G proteins through
the disruption of the Ga-Gbg interaction interface and
downstream effector interaction interfaces.9 One of the
mutations evaluated by Yoda and colleagues causes a
p.Ile80Thr substitution—observed in 3 of our 13 individ-
uals; through tandem affinity-purification and mass-spec-
trometry analyses using tagged wild-type and p.Ile80Thr5, 2016
Figure 1. Localization of GNB1 Mutations
(A) The distribution of the 13 mutations across GNB1 (GenBank: NM_002074.4) shows a preferential enrichment of de novo mutations
affecting exon 6. cd0020 represents the WD40 domain of GNB1.
(B) Molecular representation of a heterotrimeric G protein (Ga, white; Gb, green; Gg, blue) is based on a crystal structure (PDB: ID 1GP2;
DOI: http://dx.doi.org/10.2210/pdb1gp2/pdb).28 The Gb side chains of the four residues affecting a single subject are indicated in
yellow, whereas the three recurrently affected residues are indicated in red.proteins, they demonstrated that the mutant p.Ile80Thr
protein had reduced binding to almost all Ga subunits.
Interestingly, among their data, they were also able to
show that different GNB1 alleles affected different protein
interactors, suggesting variable downstream consequences
of different GNB1 mutations.9 The secure implication of
GNB1 as a neurodevelopmental-disease-associated gene
will enable future research to determine the biology of
how mutations in GNB1 contribute to the pathogenesis
of neurodevelopmental disease.
Although none of our 13 individuals have a reportedma-
lignancy, risk of malignancy is something that warrants
observation as the individuals are prospectively followed.
Also, this wouldn’t be the first time that an oncogene has
been implicated in a developmental disorder. For example,
mutations in genes that encode key components or regula-
tors of pathways that can be found constitutively activated
in many types of cancer (such as genes associated withThe AmericRASopathies, the SWI-SNF complex, and the PI3K-Akt-
mTOR pathway) are also known to be responsible for mul-
tiple groups of developmental disorders. BRAF (MIM:
164757) is one example in which somatic mutations are
known to cause various cancer types, whereas germline
mutations are a known cause of developmental disorders
such as cardiofaciocutaneous syndrome (MIM:115150),
Noonan syndrome (MIM: 613706), and LEOPARD syn-
drome (MIM: 613707). Moreover, there is evidence that a
subset of BRAF mutations can cause both developmental
disorders and cancer (c.1789C>G [p.Leu597Val] [ClinVar:
13969; GenBank: NM_004333.4]). To explore this further,
we took the list of 53 BRAF missense mutations that
were found to be recurrent (i.e., more than two observa-
tions reported among the COSMIC catalog of somatic
mutation in cancer)29 and found that 11 (~21%) of the
somatic mutations found as recurrent mutations across
tumor samples have also been linked to one or more ofan Journal of Human Genetics 98, 1001–1010, May 5, 2016 1007
cardiofaciocutaneous syndrome, Noonan syndrome, and
undefined RASopathy within ClinVar or the Human
Gene Mutation Database (HGMD) when the search is
restricted to pathogenic curated variants.
The seminal work published on the structure of GNB1
provided experimental evidence on 15 GNB1 residues—
including theprecise residues affected in8ofour13 individ-
uals—that mediate interactions with both Ga subunits and
effector proteins. According to the crystal structures of
heterotrimeric Gabg, two Gbg regions of interaction with
Ga are localized: the switch interface (Gb residues 57, 59,
98, 99, 101, 117, 119, 143, 186, 228, and 332) and the
amino-terminal interface (Gb residues 55, 78, 80, and
89).8,30 The GNB1 mutation found in individual 2
(c.233A>G [p.Lys78Arg]) affects a Gb residue reported to
be important for regulating (1) activation of adenylyl
cyclase 2, (2) inhibition of calcium channels, and (3) activa-
tion of potassium channels. The GNB1mutations found in
individuals 3, 4, and 10–12 (c.239T>C [p.Ile80Thr] and
c.239T>A [p.Ile80Asn]) affect aGb residue found important
for (1) inhibition of calcium channels, (2) activation of
potassium channels, (3) activation of phospholipase C-b2,
and (4) Ga binding. The GNB1 recurrent mutation found
in individuals 5 and 8 (c.301A>G [p.Met101Val]) affects a
Gb residue found important for (1) activation of adenylyl
cyclase 2, (2) inhibition of calcium channels, (3) activation
of phospholipase C-b2, and (4) G-protein-coupled recep-
tors.8 This existing literature highlights multiple down-
stream signaling cascades that are potentially affected by
the disruption of these specific residues. Although the rele-
vance remains unclear, eight of our identified mutations
affect the GNB1 residues found to be important for inhibi-
tion of calcium channels: Leu55, Lys78, Ile80, Met101,
Asn119, Thr143, Asp186, and Trp332.8 By plotting the
distribution of disease-associated variants on a model of
the structure of GNB1, we observed the tertiary clustering
of these substitutions in the Ga-Gbg binding region
(Figure 1B).
Interestingly, the recurring GNB1 germline de novo
mutation (c.239T>C [p.Ile80Thr]) found amongour 13 indi-
viduals has been reported in the ExAC Browser as a low-con-
fidence singleton variant (ExAC variant 1-1737942-A-G). As
highlighted by Yoda and colleagues,9 the mutation causing
the p.Ile80Thr substitution is among the most frequent so-
matic mutations reported inGNB1 tumor genetics.9 Indeed,
as expected, visually assessing the variant calls of the single
low-confidence ExAC observation makes it clear that the
variant in the ExAC Browser, if not a technical artifact, is a
post-zygotic mutation whereby only 10 variant reads out of
76 overlapping reads support the variant (i.e., ~13% of reads
support the p.Ile80Thr variant in contrast to the expected
50%; p ¼ 33 1011, two-tailed binomial exact test).
Although oncogenic mutations that result in strong
downstream signaling activation might not be compatible
with survival as germline mutations, there is already
evidence inMendeliandisease literature that some recurrent
oncogenic mutations are viable but result in various devel-1008 The American Journal of Human Genetics 98, 1001–1010, Mayopmentaldisorders.31,32 Ithasbeen suggested thatpostnatal
intervention to reduce Ras-MAPK activity could alleviate
symptoms associated with RASopathies.31 We cautiously
speculate that this paradigmmight also eventually be appli-
cable toGNB1-related disorders.GNB1 activatingmutations
studied by Yoda and colleagues were found to be responsive
to the introduction of a small-molecule inhibitor of both
PI3K andmTORpathways (BEZ235), which they found sup-
pressed PI3K-mTOR signaling and improved survival of
mice with mutant GNB1-induced leukemia.9
This study highlights how sequencing large collections
of undiagnosed individuals allows us to define the vari-
able phenotypes associated with genes such as GNB1.
Moreover, many of the GNB1 mutations identified as
germline de novo mutations in neurodevelopmental
disease have been described as important sites in tumor
genetics,9 suggesting that these mutations occur at mitot-
ically mutable GNB1 residues enriched among known
Gb interaction residues. Yet, despite the observed mitotic
mutability, this GNB1 sequence remains extremely intol-
erant to germline functional mutations in the human
population.Accession Numbers
The accession numbers for the GNB1 variants reported in this paper
are ClinVar: SCV000266332, SCV000266333, SCV000266334,
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